Beyond Pharmaceuticals: Fit-for-purpose New Approach Methodologies for Environmental Cardiotoxicity Testing

Overview

Journal ALTEX

Date 2022 Jun 1

PMID 35648122

Authors

Mark C Daley

Ulrike Mende

Bum-Rak Choi

Patrick D McMullen

Kareen L K Coulombe

Affiliations

Soon will be listed here.

Abstract

Environmental factors play a substantial role in determining cardiovascular health, but data informing the risks presented by environmental toxicants is insufficient. In vitro new approach methodologies (NAMs) offer a promising approach with which to address the limitations of traditional in vivo and in vitro assays for assessing cardiotoxicity. Driven largely by the needs of pharmaceutical toxicity testing, considerable progress in developing NAMs for cardiotoxicity analysis has already been made. As the scientific and regulatory interest in NAMs for environmental chemicals continues to grow, a thorough understanding of the unique features of environmental cardiotoxicants and their associated cardiotoxicities is needed. Here, we review the key characteristics of as well as important regulatory and biological considerations for fit-for-purpose NAMs for environmental cardiotoxicity. By emphasizing the challenges and opportunities presented by NAMs for environmental cardiotoxicity we hope to accelerate their development, acceptance, and application.

Citing Articles

Cardiomyocytes in Hypoxia: Cellular Responses and Implications for Cell-Based Cardiac Regenerative Therapies.

Dwyer K, Snyder C, Coulombe K Bioengineering (Basel). 2025; 12(2).

PMID: 40001674 PMC: 11851968. DOI: 10.3390/bioengineering12020154.

Advancing Human iPSC-Derived Cardiomyocyte Hypoxia Resistance for Cardiac Regenerative Therapies through a Systematic Assessment of In Vitro Conditioning.

Snyder C, Dwyer K, Coulombe K Int J Mol Sci. 2024; 25(17).

PMID: 39273573 PMC: 11395605. DOI: 10.3390/ijms25179627.

Informing Hazard Identification and Risk Characterization of Environmental Chemicals by Combining Transcriptomic and Functional Data from Human-Induced Pluripotent Stem-Cell-Derived Cardiomyocytes.

Tsai H, Ford L, Burnett S, Dickey A, Wright F, Chiu W Chem Res Toxicol. 2024; 37(8):1428-1444.

PMID: 39046974 PMC: 11691792. DOI: 10.1021/acs.chemrestox.4c00193.

In vitro to in vivo extrapolation from 3D hiPSC-derived cardiac microtissues and physiologically based pharmacokinetic modeling to inform next-generation arrhythmia risk assessment.

Daley M, Moreau M, Bronk P, Fisher J, Kofron C, Mende U Toxicol Sci. 2024; 201(1):145-157.

PMID: 38897660 PMC: 11347779. DOI: 10.1093/toxsci/kfae079.

Comparative cardiotoxicity assessment of bisphenol chemicals and estradiol using human induced pluripotent stem cell-derived cardiomyocytes.

Cooper B, Salameh S, Posnack N Toxicol Sci. 2024; 198(2):273-287.

PMID: 38310357 PMC: 10964748. DOI: 10.1093/toxsci/kfae015.

References

. International Conference on Harmonisation; guidance on S7A safety pharmacology studies for human pharmaceuticals; availability. Notice. Fed Regist. 2002; 66(135):36791-2. View

Chen I, Matsa E, Wu J . Induced pluripotent stem cells: at the heart of cardiovascular precision medicine. Nat Rev Cardiol. 2016; 13(6):333-49. PMC: 5917945. DOI: 10.1038/nrcardio.2016.36. View

Frommeyer G, Eckardt L . Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms. Nat Rev Cardiol. 2015; 13(1):36-47. DOI: 10.1038/nrcardio.2015.110. View

Meek M, Boobis A, Cote I, Dellarco V, Fotakis G, Munn S . New developments in the evolution and application of the WHO/IPCS framework on mode of action/species concordance analysis. J Appl Toxicol. 2013; 34(1):1-18. PMC: 6701984. DOI: 10.1002/jat.2949. View

Blinova K, Stohlman J, Vicente J, Chan D, Johannesen L, Hortigon-Vinagre M . Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias. Toxicol Sci. 2016; 155(1):234-247. PMC: 6093617. DOI: 10.1093/toxsci/kfw200. View

Sallam K, Li Y, Sager P, Houser S, Wu J . Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytes. Circ Res. 2015; 116(12):1989-2004. PMC: 4676576. DOI: 10.1161/CIRCRESAHA.116.304494. View

Ingber D . Is it Time for Reviewer 3 to Request Human Organ Chip Experiments Instead of Animal Validation Studies?. Adv Sci (Weinh). 2020; 7(22):2002030. PMC: 7675190. DOI: 10.1002/advs.202002030. View

Dix D, Houck K, Martin M, Richard A, Setzer R, Kavlock R . The ToxCast program for prioritizing toxicity testing of environmental chemicals. Toxicol Sci. 2006; 95(1):5-12. DOI: 10.1093/toxsci/kfl103. View

Ulmer B, Stoehr A, Schulze M, Patel S, Gucek M, Mannhardt I . Contractile Work Contributes to Maturation of Energy Metabolism in hiPSC-Derived Cardiomyocytes. Stem Cell Reports. 2018; 10(3):834-847. PMC: 5919410. DOI: 10.1016/j.stemcr.2018.01.039. View

10.

Feric N, Pallotta I, Singh R, Bogdanowicz D, Gustilo M, Chaudhary K . Engineered Cardiac Tissues Generated in the Biowire II: A Platform for Human-Based Drug Discovery. Toxicol Sci. 2019; 172(1):89-97. PMC: 6813749. DOI: 10.1093/toxsci/kfz168. View

11.

Wambaugh J, Wetmore B, Pearce R, Strope C, Goldsmith R, Sluka J . Toxicokinetic Triage for Environmental Chemicals. Toxicol Sci. 2015; 147(1):55-67. PMC: 4560038. DOI: 10.1093/toxsci/kfv118. View

12.

Nerbonne J, Nichols C, Schwarz T, Escande D . Genetic manipulation of cardiac K(+) channel function in mice: what have we learned, and where do we go from here?. Circ Res. 2001; 89(11):944-56. DOI: 10.1161/hh2301.100349. View

13.

Meyer T, Tiburcy M, Zimmermann W . Cardiac macrotissues-on-a-plate models for phenotypic drug screens. Adv Drug Deliv Rev. 2019; 140:93-100. DOI: 10.1016/j.addr.2019.03.002. View

14.

Zhao Y, Rafatian N, Wang E, Wu Q, Lai B, Lu R . Towards chamber specific heart-on-a-chip for drug testing applications. Adv Drug Deliv Rev. 2020; 165-166:60-76. PMC: 7338250. DOI: 10.1016/j.addr.2019.12.002. View

15.

Guo L, Coyle L, Abrams R, Kemper R, Chiao E, Kolaja K . Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013; 136(2):581-94. DOI: 10.1093/toxsci/kft205. View

16.

Archer C, Sargeant R, Basak J, Pilling J, Barnes J, Pointon A . Characterization and Validation of a Human 3D Cardiac Microtissue for the Assessment of Changes in Cardiac Pathology. Sci Rep. 2018; 8(1):10160. PMC: 6033897. DOI: 10.1038/s41598-018-28393-y. View

17.

Mironov V, Trusk T, Kasyanov V, Little S, Swaja R, Markwald R . Biofabrication: a 21st century manufacturing paradigm. Biofabrication. 2010; 1(2):022001. DOI: 10.1088/1758-5082/1/2/022001. View

18.

Polonchuk L, Chabria M, Badi L, Hoflack J, Figtree G, Davies M . Cardiac spheroids as promising in vitro models to study the human heart microenvironment. Sci Rep. 2017; 7(1):7005. PMC: 5539326. DOI: 10.1038/s41598-017-06385-8. View

19.

Pfeiffer-Kaushik E, Smith G, Cai B, Dempsey G, Hortigon-Vinagre M, Zamora V . Electrophysiological characterization of drug response in hSC-derived cardiomyocytes using voltage-sensitive optical platforms. J Pharmacol Toxicol Methods. 2019; 99:106612. DOI: 10.1016/j.vascn.2019.106612. View

20.

Schmid C, Abi-Gerges N, Leitner M, Zellner D, Rast G . Ion Channel Expression and Electrophysiology of Singular Human (Primary and Induced Pluripotent Stem Cell-Derived) Cardiomyocytes. Cells. 2021; 10(12). PMC: 8699770. DOI: 10.3390/cells10123370. View